{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:22:56Z","timestamp":1793323376949,"version":"4.5.0"},"reference-count":21,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy, safety, and role of lenacapavir (LEN) in the treatment of HIV-1 infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was performed using PubMed and Google Scholar (through March 2023) with the search term LEN and GS-6207. Other resources included abstracts presented at recent conferences, the manufacturer\u2019s Web site, and prescribing information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All relevant articles, trial updates, and conference abstracts in the English language were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Lenacapavir represents a new class of antiretrovirals (ARVs) with a novel mechanism of action as a capsid inhibitor and a unique twice-a-year subcutaneous administration schedule. Lenacapavir when combined with other ARVs has proven to benefit heavily treatment-experienced (HTE) patients with HIV-1 infection in achieving viral suppression and immune restoration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs:<\/jats:title>\n                    <jats:p>Lenacapavir is a new treatment option that patients who are HTE can consider adding as part of an ARV regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Lenacapavir is an effective and well-tolerated option for HTE patients which is a valuable addition to the arsenal of ARVs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231171375","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T01:29:35Z","timestamp":1683163775000},"page":"185-195","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5396-3044","authenticated-orcid":false,"given":"Marylee W.","family":"Tailor","sequence":"first","affiliation":[{"name":"Nova Southeastern University, Fort Lauderdale, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-9893","authenticated-orcid":false,"given":"David","family":"Koren","sequence":"additional","affiliation":[{"name":"Temple University Health System, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-0684","authenticated-orcid":false,"given":"Elizabeth M.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Nova Southeastern University, Fort Lauderdale, FL, USA"},{"name":"Memorial Healthcare System, Hollywood, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"bibr1-10600280231171375","unstructured":"Sunlenca (lenacapavir). Foster City, CA: Gilead Sciences, Inc. December 2022."},{"key":"bibr2-10600280231171375","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed February 12, 2023. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"},{"key":"bibr3-10600280231171375","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2443-1"},{"key":"bibr4-10600280231171375","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00291-0"},{"key":"bibr5-10600280231171375","unstructured":"Hagins D, Koenig E, Safran R, et al. Long-acting lenacapavir in a combination regimen for treatment na\u00efve PWH: week 80. Paper presented at the CROI; February 19-22, 2023; Seattle, WA. https:\/\/www.natap.org\/2023\/CROI\/croi_59.htm"},{"key":"bibr6-10600280231171375","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"bibr7-10600280231171375","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.108"},{"key":"bibr8-10600280231171375","unstructured":"U.S. National Institutes of Health, U.S. National Library of Medicine. Study evaluating the safety and efficacy of islatravir in combination with lenacapavir in virologically suppressed people with HIV. Accessed January 15, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05052996"},{"key":"bibr9-10600280231171375","unstructured":"Merck. Merck announces clinical holds on studies evaluating islatravir for the treatment and prevention of HIV-1 infection. December 13, 2021. Accessed January 15, 2023. https:\/\/www.merck.com\/news\/merck-announces-clinical-holds-on-studies-evaluating-islatravir-for-the-treatment-and-prevention-of-hiv-1-infection\/"},{"key":"bibr10-10600280231171375","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.12.011"},{"key":"bibr11-10600280231171375","unstructured":"Gilead Sciences. Study to assess safety and efficacy of lenacapavir and emtricitabine\/tenofovir alafenamide for pre-exposure prophylaxis in adolescent girls and young women at risk for HIV infection (PURPOSE 1). ClinicalTrials.gov Identifier: NCT04994509. Updated January 18, 2023. Accessed January 24, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04994509"},{"key":"bibr12-10600280231171375","unstructured":"Gilead Sciences. Study to assess the effectiveness and safety of lenacapavir for human immunodeficiency virus (HIV) for pre-exposure prophylaxis (PURPOSE 2). ClinicalTrials.gov Identifier: NCT04925752. Updated January 18, 2023. Accessed January 24, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04925752"},{"key":"bibr13-10600280231171375","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac364"},{"key":"bibr14-10600280231171375","doi-asserted-by":"publisher","DOI":"10.3390\/v14061202"},{"key":"bibr15-10600280231171375","unstructured":"Margot N, VanderVeen L, Naik V, Dvory-Sobol H, Rhee M, Callebaut C. Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 52 weeks of treatment. Paper presented at the 24th International AIDS Conference. Abstract 7520; July 29-August 2, 2022; Montreal, Qu\u00e9bec, Canada. https:\/\/programme.aids2022.org\/Abstract\/Abstract\/?abstractid=7520"},{"key":"bibr16-10600280231171375","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab503"},{"key":"bibr17-10600280231171375","unstructured":"VanderVeen L, Margot N, Naik V, Dvory-Sobol H, Rhee M, Callebaut C. Resistance analysis of long-acting lenacapavir in treatment-na\u00efve people with HIV at 54 weeks. Paper presented at the 24th International AIDS Conference. Abstract 7271; July 29-August 2, 2022; Montreal, Qu\u00e9bec, Canada. https:\/\/programme.aids2022.org\/Abstract\/Abstract\/?abstractid=7271"},{"key":"bibr18-10600280231171375","unstructured":"Kumar P, Gupta S, Segal-Maurer S, et al. Injection site reaction experience in clinical studies of people using lenacapavir for HIV treatment. Paper presented at the 24th International AIDS Conference. Abstract 6805; July 29-August 2, 2022; Montreal, Qu\u00e9bec, Canada. https:\/\/programme.aids2022.org\/Abstract\/Abstract\/?abstractid=6805"},{"key":"bibr19-10600280231171375","unstructured":"Weber EJ, Graham H, West SK, et al. Pharmacokinetics of lenacapavir in participants with severe renal impairment. CROI 2022. Abstract 434. Accessed April 18, 2023. https:\/\/www.hivandmore.de\/kongresse\/croi2022\/slides\/gilead\/Weber_LEN-PK-in-Renal-Impairment_CROI-2022_Poster_434.pdf"},{"key":"bibr20-10600280231171375","unstructured":"Jogiraju V, Begley R, Hindman J, et al. Pharmacokinetics of lenacapavir, an HIV-1 capsid inhibitor, in hepatic impairment. CROI 2022. Abstract 375. Accessed April 18, 2023. https:\/\/www.hivandmore.de\/kongresse\/croi2021\/slides\/gilead\/Jogiraju_LEN-PK-in-Hepatic-Impairment_CROI-2021_Poster-1315_Final.pdf"},{"key":"bibr21-10600280231171375","unstructured":"Eron JJ, Little SR, Crofoot G, et al. Lenacapavir with bNABs GS-5423 and GS-2872 dosed every 6 months in people with HIV. CROI 2023. Abstract 193. Accessed April 18, 2023. https:\/\/natap.org\/2023\/CROI\/croi_36.htm"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231171375","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231171375","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231171375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:11Z","timestamp":1777374791000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231171375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1177\/10600280231171375"],"URL":"https:\/\/doi.org\/10.1177\/10600280231171375","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]}}}